National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

tandutinib
A piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code names:CT53518
MLN518
Chemical structure name:1-piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-



Previous:Talvesta, tamibarotene, Tamiflu, tamoxifen citrate, tamsulosin hydrochloride
Next:tanespimycin, tanezumab, tanomastat, tapentadol hydrochloride ER, Tarabine PFS

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov